IGF-1 LR3: The rapid-acting growth hormone alternative

Insulin-like growth factor 1 (IGF-1) is a hormone that regulates the growth and proliferation of new cells in the body and is the major downstream target of most growth hormone therapies. Since increasing IGF-1 is the major target of growth hormone therapy, it is easy to imagine that direct treatment with IGF-1 could be more effective than growth hormone therapy, and in doing so you would be correct.

However, direct treatment with IGF-1 is a difficult feat to achieve due to its extremely short half-life (<10 minutes), but the formulation of Long arginine 3-IGF-1 (IGF-1 LR3) has made this hormone stable enough to produce systemic effects. IGF-1 LR3 has a half-life of 20-30 hours, making this compound a powerful way to increase IGF-1 levels in the body. In fact, IGF-1 LR3 has been shown to be much more effective than traditional growth hormone therapy. IGF-1 LR3 can help you gain muscle mass and strength, lose fat, and improve your overall health. If you are looking for an alternative to traditional growth hormone therapy, IGF-1 LR3 is the answer.

What is Insulin-like Growth Factor 1 (IGF-1)

Insulin-like growth factor 1 (IGF-1) is a peptide hormone produced in the liver as result of stimulation from human growth hormone (HGH). It is through the process of stimulating IGF-1 release and the effects of elevated IGF-1 levels that human growth hormone (HGH) exerts it’s main effects on forming new muscle fibers (hyperplasia), fat burning (lipolysis) and anti-aging effects on improving the quality of hair, skin and nails.

IGF-1 LR3 Vs. Human Growth Hormone (HGH)

Human Growth Hormone (HGH) is a medication that people often seek for its anti-aging, fat burning and performance enhancing benefits; although it is not legal to use for these purposes. The effects of HGH are slow going and take 2-3 months before any benefits can be seen. The same timeline applies to the commonly used Growth Hormone Releasing Peptides (GHRPs), such as sermorelin, Cjc-1295 and ipamorelin, which are very effective medications used to increase growth hormone levels. However, IGF-1 LR3 can produce the same effects as 3-6 months of growth hormone treatment in as little as 2-4 weeks. IGF-1 LR3 injections produce a rapid increase in IGF-1 levels that immediately begin to produce effects, such as increase muscle fiber density, fat-loss and increased quality of hair, skin and nails. For the above reasons we can conclude that IGF-1 LR3 is a better option for individuals that need to increase muscle fiber density and size, and those looking for rapid results that HGH and GHRP therapies cannot achieve; however, GHRPs are the best choice for those in need of anti-aging and fat loss benefits that are best achieved over time.

IGF-1 LR3 is more potent than the natural form of IGF-1

IGF-1 has long been known to be essential in promoting muscular growth and hyperplasia, the increase of muscle count in a single muscle fiber. And now, with IGF-1 LR3, the process can be expedited significantly. IGF-1 LR3 has been proven to be more potent at promoting muscle movements than its natural counterparts, meaning that users can get better results from IGF-1 LR3 than from growth hormone and the natural levels of circulating IGF-1 that growth hormone produces. Despite being structurally identical to naturally produced IGF-1 (with the addition of a long arginine group) circulating IGF-1 LR3 is more potent because it is resistant to being weakened and inactivated by binding proteins that normally affect IGF-1.

It has a half-life of 20-30 hours, so it can be taken once a day

If you’re looking for the most effective way to promote muscle hyperplasia, then IGF-1 LR3 is the obvious choice. The effects IGF-1 can have on muscle repair, strength and size are too great to ignore, but short acting IGF-1 is so difficult to use that it is impractical as a medication. IGF-1 LR3, on the other hand, is relatively simple to take, with a half-life of 20-30 hours it is injected subcutaneously once daily, 5 days per week.

IGF-1 LR3 helps to build muscle mass, increase strength, and improve recovery time

Growth Hormone and Growth Hormone Releasing Peptides (GHRPs) have long been used for their ability to speed recovery from injuries, improve body composition and the quality of hair skin and nails, but IGF-1 LR3 has quickly become the go to medication for patients that need to build muscle mass.

The hormone has been proven to do much more than just increase strength and shorten recovery times; IGF-1 LR3 stimulates hyperplasia, the actual growth of new muscle cells, leading to improved muscle symmetry and even greater gains in muscular size and strength. Don’t underestimate the importance of symmetry either; it is not uncommon for individuals to have as much of a 5 lb difference in muscle mass between each side of the body, and these asymmetries can lead to new or further injury.

IGF-1 LR3 is virtually the only medication available that can help to treat muscular asymmetry, and as such is a powerful tool for preventing injury in aging adults and even younger athletes that are at serious risk of life long injury if not resolved.

It can also help to burn fat and increase energy levels

Treatment with growth hormone has been touted as an excellent way to shed stubborn body fat and increase energy levels, but regulatory agencies in the United States have disallowed the use of growth hormone for these purposes. Luckily, GHRPs like CJC-1295, ipamorelin and sermorelin can safely be used to produce significant increases in growth hormone levels and are still available for use by patients that benefit from growth hormone treatment. While these peptides do produce a notable advantage over IGF-1 LR3 in their ability to directly activate lipolysis to burn fat and increase energy levels, IGF-1 LR3 can certainly help. By activating cellular growth pathways the body naturally responds by utilizing stored fatty acids, and this can help produce a noticeable reduction in body fat.

IGF-1 LR3 is a safe and effective alternative to other growth hormones on the market

If you are looking for a more effective, yet safe, form of growth hormone, IGF-1 LR3 is an excellent option. When dosed property, IGF-1 LR3 has a low risk of side effects and heightened results compared to other growth hormone medications, making this one of the most popular choices as a muscle hyperplasic agent. This reliable medication has gained significant attention from athletes, biohackers, and even scientists who look for improved lean muscle growth and fat loss.

Many users report better quality sleep, increased energy levels and mental clarity, along with a positive stabilization in blood sugar levels. By taking just one vial per month, there is already extraordinary efficacy in such a short amount of time. If you’re looking for quick and long-term health benefits safely & easily accessible over the counter, look no further than IGF-1 LR3!

IGF-1 LR3 is an incredibly powerful growth hormone that can have a huge impact on your health and fitness. If you’re looking for something that will help you build muscle mass, increase strength, and improve recovery time, IGF-1 LR3 is a great option. In addition to its benefits for athletes, IGF-1 LR3 can also help to burn fat and increase energy levels. It’s a safe and effective alternative to other growth hormones on the market, so if you’re looking for a way to take your wellness to the next level, give it a try!

Works Cited

1. Kasemkijwattana C, Menetrey J, Bosch P, Somogyi G, Moreland MS, Fu FH, Buranapanitkit B, Watkins SS, Huard J. Use of growth factors to improve muscle healing after strain injury. Clin Orthop. 2000;370:272–285.
2. Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle. 2011;1(1):4. Published 2011 Jan 24. doi:10.1186/2044-5040-1-4
3. Junilla RK, List EO, Berryman DE,et al. The GH/IGF-1 axis in aging and longevity. Nat Rev Endocrinol. 2013;9(6):366-76
4. Cappola AR, Bandeen-Roche K, Wand GS, et al. Association of IGF-1 levels with muscle strength and mobility in older women.
5. Aguirre GA, Rodriguez J, de la Garza RG, et al. Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med. 2016;14:3.
6. Kawai M, Rosen CJ. The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J Cell Biochem. 2010;111(1):14-19. J Clin Endocrinol Metab. 2001;86(9):4139-46.
7. Garoufalia Z, Papadopetraki A, Karatza E, Vardakostas D, Philippou A, Kouraklis G, Mantas D. Insulin-like growth factor-I and wound healing, a potential answer to non-healing wounds: A systematic review of the literature and future perspectives. Biomed Rep. 2021 Aug;15(2):66. doi: 10.3892/br.2021.1442. Epub 2021 Jun 8. PMID: 34155450; PMCID: PMC8212444.
8. Lu H, Huang D, Saederup N, Charo IF, Ransohoff RM, Zhou L. Macrophages recruited via CCR2 produce insulin-like growth factor-1 to repair acute skeletal muscle injury. FASEB J. 2011;25:358–369. doi: 10.1096/fj.10-171579.
9. Antoine Salzmann, Sarah-Naomi James, Dylan M Williams, Marcus Richards, Dorina Cadar, Jonathan M Schott, William Coath, Carole H Sudre, Nishi Chaturvedi, Victoria Garfield, Investigating the Relationship Between IGF-I, IGF-II, and IGFBP-3 Concentrations and Later-Life Cognition and Brain Volume, The Journal of Clinical Endocrinology & Metabolism, Volume 106, Issue 6, June 2021, Pages 1617–1629.
10. Zeinab Sarem, Christiane Bumke-Vogt, Ayman M Mahmoud, Biruhalem Assefa, Martin O Weickert, Aikatarini Adamidou, Volker Bähr, Jan Frystyk, Matthias Möhlig, Joachim Spranger, Stefanie Lieske, Andreas L Birkenfeld, Andreas F H Pfeiffer, Ayman M Arafat, Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins, The Journal of Clinical Endocrinology & Metabolism, Volume 102, Issue 9, 1 September 2017, Pages 3480–3490, https://doi.org/10.1210/jc.2017-00558
11. Provenzano PP, Alejandro-Osorio AL, Grorud KW, Martinez DA, Vailas AC, Grindeland RE, Vanderby R Jr. Systemic administration of IGF-I enhances healing in collagenous extracellular matrices: evaluation of loaded and unloaded ligaments. BMC Physiol. 2007 Mar 26;7:2. doi: 10.1186/1472-6793-7-2. PMID: 17386107; PMCID: PMC1851714.
12. Elaine Emmerson, Laura Campbell, Faith C.J. Davies, Nina L. Ross, Gillian S. Ashcroft, Andrée Krust, Pierre Chambon, Matthew J. Hardman, Insulin-Like Growth Factor-1 Promotes Wound Healing in Estrogen-Deprived Mice: New Insights into Cutaneous IGF-1R/ERα Cross Talk, Journal of Investigative Dermatology, Volume 132, Issue 12, 2012, Pages 2838-2848, ISSN 0022-202X, https://doi.org/10.1038/jid.2012.228.
13. Scavo LM, Karas M, Murray M, Leroith D. Insulin-like growth factor-I stimulates both cell growth and lipogenesis during differentiation of human mesenchymal stem cells into adipocytes. J Clin Endocrinol Metab. 2004;89:3543-3553.
14. Khamsi, F., Roberge, S., Yavas, Y. et al. Recent discoveries in physiology of insulin-like growth factor-1 and its interaction with gonadotropins in folliculogenesis. Endocr 16, 151–165 (2001). https://doi.org/10.1385/ENDO:16:3:151
15. Higashi Y, Quevedo HC, Tiwari S, et al. The interaction between IGF-1, atherosclerosis and vascular aging. Front Horm Res. 2014;43:107-124
16. Higashi Y, Pandey A, Goodwin B, Delafontaine P. Insulin-Like Growth Factor-1 Regulates Glutathione Peroxidase Expression and Activity in Vascular Endothelial Cells: Implications for Atheroprotective Actions of Insulin-Like Growth Factor-1. Biochim Biophys Acta. 2013;1832:391–399.